□□

□□□□□□□□□□□□TSC□

□□□□□□□ □□□□□□□□□□□□

□□

□□□

□□□□□□□□□□□□□□□□□□□□□□□□1985□□□□□□□□□□□□□□□□□□□□□□□□□□□□[1]□□□□□□□□□□□□□1,400□1,800□□1993□□□□□□1,600□2,000□□□□□□□□□□□□□□□□□□□□□□□□□□□□**1**□□□□□□□□□□□□□□□5□10□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□10,000□□1□□□□□□□□□□[1-3]□

□□□□□□□□15,000□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□[1,3]□□□□□□□□□□□□□□□□6,000□□1□□□□□□□□□□□□□100□□□□□□□□□□□□□□□□□□□□□□□□□□□□□[4,5]□

□□□□□□□□□□□□□□□□□□□□□□□□□3□□2□□□□□□□□□□□□□□□□□□3□□1□□[6]□

□**1**□□□□□□□□□□□□□□□**1993**□□□□

□□	□□□□		
	□□□%□	□□□%□	□□□%□
0□	178□79.1□	195□84.8□	373□82.0□
5□	17□7.6□	13□5.7□	30□6.6□
10□	10□4.4□	17□7.4□	27□5.9□
15□	10□4.4□	5□2.2□	15□3.3□
20□	3□1.3□	0□0.0□	3□0.7□
25□	4□1.8□	0□0.0□	4□0.9□
30□	1□0.4□	0□0.0□	1□0.2□
35□	1□0.4□	0□0.0□	1□0.2□
40□			
45□	1□0.4□	0□0.0□	1□0.2□
□□	225□49.5□	230□50.5□	455□100.0□

Agata T. Gann Monograph on Cancer Research 1999; 46: 27-35

2013[illegible]

[illegible]166[illegible]2013[illegible]**2**[illegible][7][illegible]2001[illegible]1[illegible]2011[illegible]3[illegible] [illegible]SEGA[illegible]1 2[illegible]2 63%[illegible]1 20[illegible]1 42[illegible]3[illegible]1 65[illegible]TSC2[illegible]1 32[illegible][8)-11)][illegible]1[illegible]p<0.0001[illegible]2[illegible]p[illegible]0.0005[illegible]χ^2[illegible]3 93[illegible]3 83%[illegible]NMI[illegible]3 39%[illegible]3[illegible]p<0.0001[illegible]χ^2[illegible]

[illegible]2[illegible]

[illegible]	[illegible]%[illegible]	95% CI	[illegible]	p[illegible]	[illegible]
[illegible]					
[illegible]SEGA[illegible]	77	70-84	50-100	1.00	ND
SEGA	2	0-5	10-35	<0.0001	L
[illegible]	63	56-70	75-95	0.0005	L
[illegible]	20	14-26	50	<0.0001	L
[illegible]	42	34-49	65-75	<0.0001	L
Level 3	3.6	1-6			
Level 2	21	15-27			
Level 1	17	11-23			
[illegible]	21	15-27	25-50	0.24	ND
[illegible]	71	64-78	64-78		
[illegible]	61	53-69	45-55	1.00	ND
>4cm	29	22-36			
[illegible]	28	21-35	15-32	0.65	ND
[illegible]	2.6	0-5	2	0.59	ND
[illegible]	79	71-87			
[illegible]LAM	39	29-49	2-40	0.92	ND
MMPH	71	62-80			
[illegible]	98.8	97-100			
[illegible]	93	89-97	75-80	<0.0001	H
[illegible]	46	38-54	12-40	0.13	ND
[illegible] (>3)	65	58-72	>90	<0.0001	L
[illegible]	83	77-89	20-57	<0.0001	H
[illegible]	64	57-71	15-80	1.00	ND
[illegible]	49	39-59			

□□□□□□□□□	□□□□□%□	**95% CI**	□□	p□	□□
□□□□□	46	37-55	40-60	0.90	ND
□□□□□□□>20□□□□□					
□□□□□>20□□	57	43-71			
□□□□	28	14-42			
□□□□□□					
□□□	27	18-36			
□□□□					
TSC1	28	18-38	20	0.08	ND
TSC2	32	21-43	66	<0.0001	L
□□□□□□□NMI□	39	30-52	20	<0.0001	H

SEN□□□□□□
SEGA□□□□□□□□□□□□
□LAM□□□□□□□□□□
MMPH□multifocal micronodular pneumocyte hyperplasia
CI□□□□□
H□□□□□□
L□□□□□□
ND□□□□□□
χ^2□□

Wataya-Kaneda M, et al. PLoS ONE 2013; 8: e63910

□□□□□□□□□□□□□□□50□□□□80□□20□□□□52□□□□□□□□□□□□□□□□130□□90□□□□□□□□□□36□□10□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□10□19□□□□□□30□39□□□□□□**1**□□

Image

図1　男女別・年齢期別の患者分布



□□□□□□□□□□

□□□
□□□□□□□□□□□□□□□□10□□□□□□□□[□□□□](#)□□□□□□□10□□□□□□□□[□AML](#)□□□□10□40□□□□□
[□SEGA](#)□□□□□□□□□□□□□40□□□□□□[□LAM](#)□□□□□□□□□□□□□□□□□□□□□□□□□□□[□□□□](#)□□□□□□
□□40□□□□□□□□□[6) 12□]□□**2**□□□□□□□□□□□□□□□□□□□□□□□□□□□

Image



□□□□

1) Agata T. Gann Monograph on Cancer Research 1999; 46: 27-35
2) Agata T, et al. Annual Report of the Research Committee of Neurocutaneous Syndrome, the Ministry of Health and Welfare 1994: 8-14
3) Ahlsén G, et al. Arch Neurol 1994; 51: 76-81
4) National Institute of Neurological Disorders and Stroke(NINDS).National Institute of Health(NIH).Tuberous Sclerosis Fact Sheet.2012.
5) Osborne JP, et al. Ann N Y Acad Sci 1991; 615: 125-127
6) Umeoka S, et al. Radiographics 2008; 28: e32
7) Wataya-Kaneda M, et al. PLoS ONE 2013; 8: e63910
8) Dabora SL, et al. Am J Hum Genet 2001; 68: 64-80
9) Sancak O, et al. Eur J Hum Genet 2005; 13: 731-741.
10) Chopra M, et al.J Paediatr Child Health 2011; 47: 711-716.
11) Hallett L, et al.Curr Med Res Opin 2011; 27: 1571-1583.
12□Shepherd CW, et al. Mayo Clin Proc 1991; 66: 792-796

□□□□□□□□□□□□□□□□

□□□□□□

Source URL: *https://www.loadtest.pro.novartis.com/products/afinitor/tsc/overview_01*